Chen, D.; Gallagher, S.; Monson, N.L.; Herbst, R.; Wang, Y.
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J. Clin. Med. 2016, 5, 107.
https://doi.org/10.3390/jcm5120107
AMA Style
Chen D, Gallagher S, Monson NL, Herbst R, Wang Y.
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. Journal of Clinical Medicine. 2016; 5(12):107.
https://doi.org/10.3390/jcm5120107
Chicago/Turabian Style
Chen, Ding, Sandra Gallagher, Nancy L. Monson, Ronald Herbst, and Yue Wang.
2016. "Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies" Journal of Clinical Medicine 5, no. 12: 107.
https://doi.org/10.3390/jcm5120107
APA Style
Chen, D., Gallagher, S., Monson, N. L., Herbst, R., & Wang, Y.
(2016). Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. Journal of Clinical Medicine, 5(12), 107.
https://doi.org/10.3390/jcm5120107